{"id":685528,"date":"2024-01-23T18:06:01","date_gmt":"2024-01-23T18:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=685528"},"modified":"2024-01-23T18:06:01","modified_gmt":"2024-01-23T18:06:01","slug":"autoinjectors-market-analysis-revenue-trends-company-profiles-revenue-share-till-2028","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/autoinjectors-market-analysis-revenue-trends-company-profiles-revenue-share-till-2028_685528.html","title":{"rendered":"Autoinjectors Market Analysis, Revenue Trends, Company Profiles, Revenue Share Till 2028"},"content":{"rendered":"
\n
\"Autoinjectors<\/a><\/div>\n
\n
Browse 421 market data Tables and 59 Figures spread through 328 Pages and in-depth TOC on “Autoinjectors Market by Usage (Reusable, Disposable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Anaphylaxis), Route of administration (SC, IM), Volume (<3ml, >3ml), End User (Home Care, Hospitals) – Global Forecast to 2028<\/div>\n<\/div>\n<\/div>\n
North America is expected to hold a significant share of the global auto-injectors market during the forecast period. The factors such as early adoption of technologically advanced products and product approvals as well rising prevalence of chronic diseases boost the market in the region.<\/div>\n

Autoinjectors Market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $1.7 billion by 2028, growing at a CAGR of 14.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. Whereas, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%. Some of the prominent factors driving the growth of this market are favorable government support and reimbursements and growing number of regulatory approvals for autoinjectors.<\/p>\n

Request Sample Pages: <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=173991724<\/strong><\/a><\/p>\n

Prominent players in the market are <\/strong><\/p>\n

Becton, Dickinson and Company (BD) (US), Ypsomed Holding AG (Switzerland), SHL Medical (Switzerland), West Pharmaceutical Services, Inc. (US), Recipharm AB (Sweden), Haselmeier GmbH (Germany), Owen Mumford Ltd. (UK), Gerreshiemer AG (Germany), Philip-Medisize, LLC (US), Oval Medical Technologies Ltd. (UK), Solteam Incorporation Co., Ltd. (China), Elcam Drug Delivery Devices (E3D) (Israel), Antares Pharma, Inc. (US), Jabil, Inc. (US), and the some of the major market players for finished formulations covered in this chapter include AbbVie Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Novartis AG (Switzerland), Merck KGaA (Germany), Viatris Inc. (US), and Biogen (US).<\/p>\n

BD<\/strong> is the leading players in the global autoinjector devices market. The company offers self-injection device systems.<\/p>\n

Ypsomed Holding AG<\/strong> is one of the leading players in the global autoinjector devices market. Ypsomed  offers self-injection device systems along with infusion systems.<\/p>\n

Rheumatoid Arthritis subsegment accounted for the largest share of the autoinjectors market by therapy area<\/strong><\/p>\n

Among the therapy area, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapy areas. the rheumatoid arthritis segment accounted for the largest share of the autoinjectors market by therapy area.<\/p>\n

Disposable usage is the fastest-growing segment of the autoinjectors market by usage<\/strong><\/p>\n

the disposable segment accounted for the fastest-growing share of the usage segment of autoinjectors market. Market growth can largely be attributed to the high convinience and ease of use for patients as the need for manual loading of drug in the injector is eliminated due to presence of prefilled syringe, and low chances of infections through used needle.<\/p>\n

Inquire Before Buying @ <\/strong>https:\/\/www.marketsandmarkets.com\/Enquiry_Before_BuyingNew.asp?id=173991724<\/strong><\/a><\/p>\n

Europe: The second-largest region in the autoinjectors market.<\/strong><\/p>\n

The European autoinjectors market is the second-largest autoinjectors market globally, mainly due to factors such as presence of a large geriatric population in the region and the improving reimbursement and regulatory scenario. The presence of large geriatric population in the region is expected to increase the prevalence of chronic diseases leading consequently leading to growing adoption of autoinjectors for treatment of these disease.<\/p>\n

This report categorizes the Autoinjectors Market market to forecast revenue and analyze trends in each of the following submarkets:<\/strong><\/p>\n

By Usage<\/strong><\/p>\n